65th ASH Annual Meeting & Exposition: ASH Poster Walk on What's Hot in Sickle Cell Disease Clinical Research in 2023

ASH Poster Walks

adult, Sickle Cell Disease, Biological therapies, Clinical Practice (Health Services and Quality), elderly, pediatric, Diversity, Equity, and Inclusion (DEI) , Hemoglobinopathies, Gene Therapy, Diseases, Therapies, pregnant, young adult , Human, Transfusion, Study Population, Maternal Health

(Virtual Program)

Over the past decade, clinical research has led to much progress in Sickle Cell Disease (SCD) management, identifying novel therapeutic targets and FDA approval of two new therapies, crizanlizumab and voxelotor, in the fall of 2019. Numerous clinical trials of novel therapeutics and potential curative therapies are ongoing. Large patient registries from the US and Europe have begun to increase our understanding of the disease and its complications. This year’s poster walk will feature six posters that reflect the breadth of SCD clinical research taking place internationally with an emphasis on newer therapies, clinical outcomes and predictors of vaso-occlusive events and acute chest syndrome and end-organ complications of the disease. This session aligns with the ASH Research Priorities of studying hematologic diseases across the lifespan with an emphasis on the use of large datasets.

3892

Clinical and Epidemiological Characteristics of Patients Admitted with Acute Chest Syndrome on a National Scale and Factors Affecting Clinical Outcomes in Inpatient Setting

Mohamad El Labban, MD¹^*, Sumeet Kumar Yadav, MD²^*, Syed Muhammad Usama, MD³^*, Guleid Hussein, MD²^*, Syed A Khan, MD⁴^* and Karan Seegobin, MBBS⁵

¹Department of Internal Medicine, Mayo Clinic Health System, Mankato, MN
²Department of Hospital Internal Medicine, Mayo Clinic Health System, Mankato, MN
³Department of Internal Medicine, Nazareth Hospital, Philadelphia, PA
⁴Mayo Clinic Health System, Mankato, MN
⁵Department of Medical Oncology, Mayo Clinic Health System, Mankato, MN

2527

Over 4 Years of Safety and Efficacy with Voxelotor Treatment for Patients with Sickle Cell Disease: Updated Results from an Open-Label Extension of the Phase 3 HOPE Trial

Maureen Okam Achebe, MD, MPH¹, Hoda MA Hassab, MD²^*, Salam Al-Kindi³^*, Clark Brown, MD, PhD⁴, Paul Telfer, MD⁵^*, Bart J. Biemond⁶, Thokozeni Lipato⁷^*, Mark Davis⁸^*, Sarah Gray⁸^* and Victor R. Gordeuk, MD⁹

¹Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
²Alexandria University, Alexandria, Egypt
³Sultan Qaboos University, Muscat, Oman
⁴Pfizer Inc, Norcross, GA
⁵Royal London Hospital, Barts Health NHS Trust, London, United Kingdom
⁶Department of Hematology, Amsterdam University Medical Centers, location University of Amsterdam, Amsterdam, Netherlands
⁷Virginia Commonwealth University Medical Center, Richmond, VA
⁸Pfizer Inc., South San Francisco, CA
⁹Sickle Cell Center, University of Illinois at Chicago, Chicago, IL

2512

Sickle Cell Disease and Hydroxyurea Knowledge, Views and Perceptions Among 400 Sickle Cell Patients and Caregivers at Mulago Hospital Sickle Cell Clinic: A Global Health Study in Kampala, Uganda

Amanda Walker, MD¹^*, Surabhi Batra, MD, MBBS²^*, Kristin Wong, MD¹^* and Philip Kasirye, MD³^*

¹Rutgers-New Jersey Medical School, Newark, NJ
²Children’s Hospital of New Jersey, Newark Beth Israel Medical Center, Newark, NJ
³Mulago National Referral Hospital, Kampala, Uganda

Sickle Cell Trait and Mortality Risk: California Newborn Screening Longitudinal Follow up of Births 1991-2013

Susan Paulukonis, MA, MPH

Public Health Institute, Alameda, CA

1124

Persistent Albuminuria and Chronic Kidney Disease in Adults with Sickle Cell Disease: Results from a Multicenter Natural History Study

Vimal K. Derebail, MD¹, Laura Y. Zhou, PhD²^*, Yihan Tang, MS³^*, Laila Elsherif, PhD⁴, Kammie L. Patillo, RN⁵^*, David Wichlan⁶^*, Kristina Landes, MPH⁷^*, Paula McCune, RN⁸^*, Laura R. Loehr, MD, PhD, MS⁹^*, Payal Desai, MD¹⁰, Robert Cronin, MD, MS¹¹, Jianwen Cai, PhD³^* and Kenneth I. Ataga, MD^12,13

¹UNC Kidney Center, Division of Nephrology and Hypertension, University of North Carolina, Chapel Hill, NC
²Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC
³Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC
⁴Center for Sickle Cell Disease, University of Tennessee Health Sciences, Memphis, Memphis, TN
⁵Clinical Trials Unit, Office of Research, University of Tennessee Health Science Center, Memphis, TN
⁶University of North Carolina At Chapel Hill, Chapel Hill, NC
⁷The Ohio State University, Columbus, OH
⁸Clinical Trials Unit, University of Tennessee Health Science Center, Memphis, TN
⁹Division of General Internal Medicine, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC
¹⁰Levine Cancer Institute, Department of Hematology, Atrium Health, Charlotte, NC
¹¹Department of Internal Medicine, The Ohio State University, Columbus, OH
¹²Center for Sickle Cell Disease, University of Tennessee Health Sciences Center, Memphis, TN
¹³Methodist Comprehensive Sickle Cell Center, Memphis, TN

2503

Atrial Arrhythmia in Sickle Cell Anemia: A Missing Piece to Prevent Cerebrovascular Complications?

Thomas d'Humières, MD¹^*, Zineb Sadraoui²^*, Laurent Savale, MD, PhD³^*, Laurent Boyer, MD, PhD⁴^*, Gonzalo De Luna, MD⁵^*, Anoosha Habibi, MD⁶, Laurent Messonier⁷^*, David Calvet, MD, PhD⁸^*, Nicolas Lellouche, MD, PhD⁹^*, Geneviève Derumeaux, MD, PhD¹⁰^* and Pablo Bartolucci, MD, PhD⁵^*

¹Physiology Department, FHU SENEC, INSERM IMRB U955, Henri-Mondor University Hospital- UPEC, AP-HP, Creteil, France
²Physiology, Henri Mondor teaching hospital, Créteil, France
³Kremblin Bicêtre teaching hospital, Le Kremlin Bicêtre, FRA
⁴CHU Henri Mondor, Créteil, France
⁵Sickle Cell Referral Center, Henri-Mondor University Hospital- UPEC, AP-HP, Creteil, France
⁶Sickle Cell Referral Center, Henri-Mondor University Hospital- UPEC, AP-HP, Creteil Cedex, FRA
⁷Inter-university Laboratory of Human Movement Sciences EA 7424, Université Savoie Mont Blanc,, Chambéry, France
⁸Centre Hospitalier Sainte-Anne, Paris, France
⁹Cardiology Department, Henri Mondor Hospital, Assistance Publique HôPitau, CréTeil, FRA
¹⁰CHU Henri Mondor, FHU SENEC, Créteil, France

See more of: ASH Poster Walks

<< Previous Poster Walk Application | Next Poster Walk Application >>